“We are extremely pleased to receive the SHONIN approval from PMDA. We truly believe that this official approval by our government may be the start of a very bright future for the EndoPAT in Japan,” said Mr. Yasunori Noto, President of CCI Corporation, an Itamar-Medical distributor in Japan.
“The world is beginning to discover the revolutionary insight offered by EndoPAT as part of the process in early detection and prevention of cardiovascular heart disease,” said Dr. Dov Rubin, Itamar’s President & CEO.
Many EndoPAT systems have been sold in over 40 countries. It is used by Mayo Clinic, in Framingham Heart Study and in many trials by pharmaceutical companies searching for new ways to treat and prevent heart disease as well as detecting adverse affects before they occur.
